Skip to main content

Table 4 Univariate Cox regression analysis influencing outcome in the ever and never treated IPF-AE groups

From: Survival in Idiopathic pulmonary fibrosis acute exacerbations: the non-steroid approach

Variable

HR

95 % CI

p-value

Age

0.968

0.919–1.020

0.221

Gender

1.927

0.600–6.186

0.270

Smoking (pack-years)

1.000

0.980–1.020

0.996

FEV1 (% predicted)

1.000

0.941–1.063

0.990

FVC (% predicted)

1.001

0.961–1.043

0.943

TLC (% predicted)

1.034

0.976–1.096

0.252

DLCO (% predicted)

1.044

0.963–1.319

0.293

Charlson comorbidity index

0.729

0.466–1.143

0.169

LTOT

1.138

0.356–3.631

0.829

Pattern of GGO in HRCT

1.650

0.737–3.696

0.223

PO2/fiO2

0.990

0.980–1.001

0.067

NIMV

2.014

0.449–9.039

0.361

Mechanical ventilation

1.966

0.646–5.992

0.234

Disease duration

1.014

0.995–1.034

0.156

Previous corticosteroid use (all exacerbation events)

3.544

1.090–11.514

0.035

Previous corticosteroid use (unique patients)

1.642

0.441–6.119

0.460

BAL performed

0.676

0.188–2.427

0.548

6MWD

0.999

0.994–1.005

0.918

  1. IPF-AE idiopathic pulmonary fibrosis acute exacerbation; FVC forced vital capacity; FEV 1 forced expiratory volume in first second; TLC total lung capacity; DLCO diffusing capacity of the lung in carbon monoxide; LTOT long-term oxygen therapy; GGO ground glass opacities; HRCT high-resolution computerized tomography; PO 2 arterial pressure of oxygen; fiO 2 fraction of inspired oxygen; NIMV non-invasive mechanical ventilation; BAL bronchoalveolar lavage; 6MWD six minute walking distance; HR hazard ratio; CI confidence of interval